0000950170-23-053817.txt : 20231017 0000950170-23-053817.hdr.sgml : 20231017 20231017174819 ACCESSION NUMBER: 0000950170-23-053817 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231013 FILED AS OF DATE: 20231017 DATE AS OF CHANGE: 20231017 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KASINGER JAMES R. CENTRAL INDEX KEY: 0001708172 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37923 FILM NUMBER: 231330498 MAIL ADDRESS: STREET 1: C/O CRISPR THERAPEUTICS, INC. STREET 2: 610 MAIN STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CRISPR Therapeutics AG CENTRAL INDEX KEY: 0001674416 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 473173478 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 BUSINESS PHONE: 6173154600 MAIL ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 4 1 ownership.xml 4 X0508 4 2023-10-13 0001674416 CRISPR Therapeutics AG CRSP 0001708172 KASINGER JAMES R. C/O CRISPR THERAPEUTICS 105 WEST FIRST STREET BOSTON MA 02127 false true false false General Counsel and Secretary false Stock Option (Right to Buy) 44.31 2023-10-13 4 A false 16667 0 A 2033-10-13 Common Shares 16667 16667 D Restricted Stock Units 2023-10-13 4 A false 6340 0 A Common Shares 6340 6340 D This option was granted on October 13, 2023 with respect to 16,667 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 13, 2023. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. This restricted stock unit award was granted on October 13, 2023 with respect to 6,340 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026. /s/ Elizabeth Ryland Waldinger, attorney-in-fact 2023-10-17